Bernstein Cools Market’s BioNTech Fever Even as New Fast-Track Approval Adds Pipeline Spark

Bernstein warns market overestimates BioNTech's oncology pipeline potential, but FDA fast-track designation and €16.8B cash position offer a counterweight before key ASCO data readouts.

BioNTech heads into next week’s ASCO conference in Chicago with two contrasting narratives vying for investors’ attention. On one hand, a new analyst initiation from Bernstein threatens to dampen the bullish mood around the German biotech’s oncology pipeline. On the other, the company won a regulatory fast-track designation for another cancer candidate just days before the data drop — offering a counterweight to the skepticism.

Bernstein analyst Jeffrey Walch kicked off coverage with a Market Perform rating and a $96 price target, sending a cautious signal that stands out against the more optimistic calls from Deutsche Bank, Goldman Sachs and Jefferies, which all rate the stock a Buy. Walch’s central argument is that the market is overestimating the commercial potential of BioNTech’s late-stage drug candidates. His firm’s risk-adjusted peak sales estimates for the pipeline come in roughly 43% below consensus.

The biggest bone of contention is pumitamig (BNT327), the company’s lead bispecific immunomodulator and the most closely watched programme ahead of ASCO. Bernstein questions both the probability of success and the expected market share for the PD-L1/VEGF class, arguing that sell-side projections have grown too optimistic.

What keeps Walch from assigning an Underperform rating is the sheer financial firepower BioNTech holds. With €16.8 billion in cash and securities and a $1 billion share buyback programme running over twelve months, the company can afford to advance other drug candidates with higher success probabilities. That balance sheet safety net, combined with residual Covid vaccine revenue, makes BioNTech a different proposition from smaller oncology pure-plays that Bernstein has rated negatively.

The timing of the cautionary note is deliberate. ASCO, which runs from 29 May to 2 June, will see BioNTech present two oral presentations and four poster contributions. The data will be the first major read-through for pumitamig and for gotistobart, another later-stage candidate. But the pipeline extends well beyond those two drugs. The company currently has more than 25 clinical trials in phase 2 and 3, including 13 pivotal studies, and plans to launch six additional phase 3 trials in 2026, bringing the total to 15. Seven late-stage data readouts are on the horizon.

Adding to the mix is BNT113, an mRNA-based cancer immunotherapy that targets the E6 and E7 proteins of the HPV16 virus. In January, the FDA granted it Fast-Track designation for HPV16-positive squamous cell carcinoma of the head and neck with PD-L1 expression. The ongoing AHEAD-MERIT study is testing BNT113 in combination with Merck’s Keytruda (pembrolizumab) against the checkpoint inhibitor alone as a first-line therapy in unresectable or metastatic disease. BNT113 is one of the few candidates in the head-and-neck space to have reached phase II/III, alongside programmes from GSK and Ipsen, in a field that counts more than 25 active developers.

The broader precision oncology market, valued at $132.9 billion in 2025, is projected to grow to roughly $341.5 billion by 2035 — a compound annual rate of nearly 10%, fuelled by rising cancer prevalence, demand for personalised medicine and advances in genomics. That tailwind supports BioNTech’s long-term transformation from a single-product vaccine company into a diversified oncology player.

Yet the stock price tells a more cautious story. BioNTech’s shares currently trade around €79.80, about 22% below the 52-week high of €101.90 and below both the 50-day moving average of €80.99 and the 200-day average of €86.39. Bernstein’s $96 target sits just above the short-term average, implying limited upside if the ASCO results fail to deliver the validation the market is waiting for. J.P. Morgan, meanwhile, remains on the sidelines with a Hold rating — a reminder that the analyst crowd is far from united.

For BioNTech, next week is a defining moment. The cash cushion buys time, but as the Bernstein note underscores, the market wants proof that the pipeline can deliver revenue that matches the hype. If pumitamig and gotistobart meet expectations, the stock could break out of its sideways drift. If the data disappoint, the pressure will only mount.